Founder Who Sold Byte for $1.04B Starts Over: 20,000 Patients in 28 Months

Wesley Lones sold his previous company, Byte, for $1.04 billion — and his planned two-year break from work, by his own count, "lasted about seven minutes." He's back with Daybreak, a bootstrapped telehealth platform that has treated more than 20,000 sleep apnea patients in roughly its first 28 months, according to Lones.

Daybreak runs entirely from home. Patients receive a small wireless sleep-test device that wraps around a finger and tracks their sleep. A doctor reviews the data and issues a diagnosis. Qualifying patients then get an impression kit in the mail, which Daybreak uses to produce a custom-fit oral appliance — a mouthguard that gently moves the lower jaw forward to keep the airway open. Nobody sets foot in a doctor's office.

Why target sleep apnea?

The market gap is enormous. As many as 83 million U.S. adults suffer from obstructive sleep apnea, a condition that causes them to stop breathing repeatedly during sleep, waking up dozens or even hundreds of times a night. Many go untreated.

The standard therapy is a CPAP machine, which pushes pressurized air through a mask to keep the airway open. It works. Millions of patients simply can't tolerate it.

"I spent two years looking over my shoulder thinking, how could the most advanced wealthy country in the history of the world have millions of people suffering from an ailment and not have a treatment," Lones said. "I must be missing something."

What he found was that the treatment itself was the barrier. Patients hate sleeping with a mask strapped to their face. Lones has no quarrel with the technology itself. "It's the gold standard," he says. "I'm not here to demonize it." He also knows there are entire Facebook support groups devoted to coping with CPAP machines.

Lones also pushes back on the notion that sleep apnea is purely a weight problem. Anatomy plays a major role: when airway muscles relax during sleep, some people's structure makes the airway more likely to narrow or collapse. Weight can worsen the problem, but it isn't necessarily the cause.

Why doesn't everyone know about oral appliances?

Oral appliance therapy isn't new. Dentists and sleep specialists have used these devices for years. Lones investigated why they weren't reaching more patients and concluded the problem was awareness, not efficacy.

"I have yet to interact with a person who has sleep apnea and hears about an oral appliance and says, 'Wow, I would never try that,'" Lones said. "The universal, consistent answer is, 'I had no idea that exists, and I would absolutely try it. How do I get started?'"

Daybreak is his answer to that question. Making millions of people aware they have sleep apnea — and that an alternative to CPAP exists — may be the company's biggest challenge, Lones said on the podcast One Day with Jon Bier.

How do you build it without investors?

Lones built Daybreak without outside funding. His previous exits gave him a head start, but the business model does most of the work. Every appliance is custom-made, so Daybreak never manufactures finished products on spec. Cash customers pay upfront; only then does the order go to the manufacturer.

"It's a reverse sort of cash cycle where we don't have to carry a bunch of inventory," Lones says.

Bootstrapping also buys speed. "We have a lot of flexibility," he says. "We have the ability to iterate, move very quickly, really compress the time between when we identify, learn there's a problem, and then react to that problem and solve it."

What's the payoff beyond revenue?

Lones describes the shift in his own motivation. One message that stuck with him came from a mother of three whose husband suffered from sleep apnea. After his first night using the device, she wrote: "Thank you. This is the first time my children have had a father and I have had a husband in three years."

"That's why I say that it started to me as a business problem. I thought, 'I think I can solve this.' Then it became a mission because I started to see the impact," Lones said.

With 83 million potential patients and no inventory drag on the balance sheet, Daybreak's growth constraint isn't manufacturing capacity — it's whether Lones can close the awareness gap faster than competitors, including well-funded CPAP alternatives, reach the same untreated millions.